This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Feb 2;388(5):464-467.

doi: 10.1056/NEJMe2213559.

Aldosterone and Treatment-Resistant Hypertension

Jane A Leopold, Julie R Ingelfinger

PMID: 36724334
DOI: 10.1056/NEJMe2213559

Editorial

Aldosterone and Treatment-Resistant Hypertension

Jane A Leopold et al. N Engl J Med. 2023.

. 2023 Feb 2;388(5):464-467.

doi: 10.1056/NEJMe2213559.

Authors

Jane A Leopold, Julie R Ingelfinger

PMID: 36724334
DOI: 10.1056/NEJMe2213559

No abstract available

PubMed Disclaimer

Comment on

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Freeman MW, et al. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7. N Engl J Med. 2023. PMID: 36342143 Clinical Trial.
Decreasing the Effects of Aldosterone in Resistant Hypertension - A Success Story.
Azizi M. Azizi M. N Engl J Med. 2023 Feb 2;388(5):461-463. doi: 10.1056/NEJMe2216143. N Engl J Med. 2023. PMID: 36724333 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information